Ascletis Pharma Inc.

First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial
2020-12-28
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
2020-12-22
Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist
2020-12-14
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
2020-12-04
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer
2020-11-30
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
2020-11-19
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
2020-11-18
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist
2020-10-12
Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020
2020-10-10
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
2020-09-14

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1